Journal of Psychedelic Studies
August 29, 2017
Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre et al.
39 citations
Patients with substance-related disorders who received ibogaine in a treatment program reported intense physical discomfort and a psychologically challenging experience, along with heightened memory retrieval—especially about past drug use—and vivid, dreamlike visions. The experience shared some features with other psychedelics but also differed markedly. The authors propose that ibogaine's subjective effects may function as simulations of threat and danger, drawing on an evolutionary theory of dreaming.
Journal of Psychedelic Studies
April 1, 2017
Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre et al.
29 citations
A treatment combining the psychedelic alkaloid ibogaine with cognitive-behavioral therapy led to improvements in craving, personal relationships, quality of life, and self-efficacy among people with substance use disorders, including cocaine dependence. These secondary outcomes were assessed through semi-structured interviews and qualitative content analysis. The findings support the therapeutic potential of ibogaine-assisted psychotherapy for treating substance use disorders, particularly for psychostimulants like cocaine and crack cocaine, for which effective treatments are lacking.
Journal of psychoactive drugs
January 1, 2024
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira et al.
7 citations
Ibogaine, a natural psychoactive drug, has been studied for treating substance use disorders since the mid-1960s. A scientometric analysis of publications from 1993 to 2022 found 1523 references, with linear growth in the first and third decades and lower average publications in 1993-2002 than in later decades. Researchers from five continents contributed, with US and Canadian academic centers most productive. Early keywords included cocaine, tobacco, morphine, and alcohol; opioids and psychedelics emerged in the third decade. Only one preclinical meta-analysis and no human meta-analyses were found. Research trends are widespread and growing, underscoring the need for rigorous clinical trials on ibogaine's efficacy and safety.